The efficacy of Polyvynilpyrrolidone-Zn Gluconate and Taurine in the Prevention of Oral Mucositis in Haematological Patients
| Autor: | Andrei Colita, Anca Colita, Alina Tanase, Cristina Jercan, Zsofia Varady, Oana Otilia Niculita, Letitia-Elena Radu |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Taurine
Process equipment business.industry Materials Science (miscellaneous) Process Chemistry and Technology General Engineering General Chemistry General Medicine Pharmacology medicine.disease General Biochemistry Genetics and Molecular Biology chemistry.chemical_compound chemistry Materials Chemistry Mucositis medicine General Pharmacology Toxicology and Pharmaceutics business |
| Zdroj: | Revista de Chimie. 71:195-205 |
| ISSN: | 2668-8212 0034-7752 |
| Popis: | Oral mucositis (OM) is a significant problem in patients undergoing standard or high-dose chemotherapy and/or radiotherapy for the management of haematological disorders, associated with patient morbidity and increased resource use. The OM management relies on supportive care and symptom palliation. This study evaluates the results of Polyvynilpyrrolidone-Zn gluconate and taurine (GelX� Oral Spray) in this setting. This is an observational, retrospective study, conducted on 145 paediatric and adult patients. All patients received GelX� Oral Spray as prophylaxis for OM. The research was supported by BMG Pharma S.p.A. The prevention of OM in patients treated with GelX� Oral Spray was reached in 54 patients (37.24%), 22 adults (22.22%) and 32 children (69.56%). A total number of 52 patients (35.86%) developed severe OM when GelX� was used as preventive treatment, 40 adults (40.4%) adults and 12 children (26.08%). Grade 4 OM developed in 16 patients (11.03%), 10 adults and 1 child (68.75%) had a complete remission of OM, while 3 adults and 2 children (31.25%) had partial remission. No patient had to interrupt chemo/radiotherapy due to OM. GelX� Oral Spray was considered safe, no adverse device effect or severe adverse device effect were considered related to the use of the product. This retrospective study supports prophylactic use of GelX� Oral Spray to minimize the risk of OM secondary to chemo/radiotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|